Study examines safety of COVID-19 vaccine in a nationwide mass-vaccination setting

The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the safety of the Pfizer/BioNTech BNT162B2 vaccine against COVID-19.

Related Keywords

Boston ,Massachusetts ,United States ,Israel ,Harvard University ,Marc Lipsitch ,Miguel Hern ,Eldad Kepten ,Jacob Waxman ,Emily Henderson ,Noam Barda ,Yair Ben Shlomo ,Isaac Kohane ,Doron Netzer ,Ben Reis ,Noa Dagan ,Reut Ohana ,Boston Children Hospital Computational Health Informatics Program ,Israel National Expert Advisory Team ,Harvard Medical School ,Francesca Berkowitz Family Living Laboratory Collaboration ,Clalit Health Services ,Berkowitz Living Laboratory Collaboration ,Clalit Research Institute ,Clalit Community Health Division ,Predictive Medicine Group ,Outcomes Analysis ,Ran Balicer ,Public Health ,Biomedical Informatics ,Boston Children ,Harvard Medical ,Chief Innovation Officer ,National Expert Advisory Team ,Chief Medical Officer ,Community Health ,Hospital Computational Health Informatics Program ,Communicable Disease Dynamics ,Clalit Research ,Medicine ,Research ,Vaccine ,Children ,Coronavirus ,Electronic Medical Records ,Healthcare ,Hospital ,Laboratory ,Lymph Nodes ,Medical School ,Myocarditis ,